• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23475 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Basque Office for Health Technology Assessment (OSTEBA) [Measurement of the fraction of exhaled nitric oxide in the diagnosis and treatment of asthmatic children]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement of preference in parodontopathy]
2015     Haute Autorite de sante (HAS) [Measurement of nitric oxide (NO) in exhaled air]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement of myocardial fractional flow reserve (FFR) in coronary heart disease]
2019     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Measurement of gastric residual volume during enteral feeding in patients hospitalized in the intensive care unit]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Measurement of fractional flow reserve to guide the decision on percutaneous coronary interventions]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure - Addendum to Commission E15-04]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III - Addendum to Project D23-02]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Measles: diagnosis and detection]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Matrix-assisted laser desorption/ionization-time of flight analyzer (MALDI-TOF) in infections]
2005     Finnish Office for Health Care Technology Assessment (Finohta) [Maternal ultrasound and serum screening in the detection of structural and chromosomal abnormalities]
2023     Basque Office for Health Technology Assessment (OSTEBA) [Massive parallel sequencing for the diagnosis of acute leukaemia]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Mason's vertical banded gastroplasty and other gastroplasties in treating obesity]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Markerless real-time monitoring surface guided radiation therapy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maribavir (cytomegalovirus infection (treatment-refractory)) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maralixibat (cholestatic pruritis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Map on shared resources in HTA and Health Services]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Map on shared resources in health technology assessment]
2013     Canary Health Service [Manual with evaluation and validation criteria for shared decision-making tools]
2009     Andalusian Health Technology Assessment Area (AETSA) [Manual to adapt health technology assessment reports to the public (MADETSCI)]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Manual suture versus mechanical suture for surgery of colorectal anastomosis]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mandibular advancement devices in mild to moderate obstructive sleep apnoea in adults]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Management of the extravasation of antineoplastic agents]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Management of patients with dyspepsia]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Management of elderly patients with chronic pathologies]
2024     Haute Autorite de sante (HAS) [Management missing teeth with implant-supported prostheses (complete edentulism or single missing teeth)]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Management and improvement in cancer pain: focusing on narcotic analgesics]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Mammography screening in the county of Funen 1993 - 1997. An HTA report]
2010     Andalusian Health Technology Assessment Area (AETSA) [Mammaprint]
2007     Norwegian Knowledge Centre for the Health Services (NOKC) [Male infertility: intracytoplasmic sperm injection (ICSI) using surgically retrieved sperm from the testis or the epididymis]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance]
2008     Committee for New Health Technology Assessment (CNHTA) [Malaria antigen, rapid]
2009     Committee for New Health Technology Assessment (CNHTA) [Malaria antigen, rapid(target Ag:Aldolase,Histidine-rich protein-2)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Magnetic resonance-compatible pacemakers]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of prostatic hyperplasia]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine myoma: (2. Addendum to Commissions E14-04 and E14-05)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine myoma (Addendum to Commissions E14-04 and E14-05)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2012     Finnish Office for Health Care Technology Assessment (Finohta) [Magnetic resonance imaging of primary breast cancer]
2008     Committee for New Health Technology Assessment (CNHTA) [Magnetic Resonance Imaging guided high intensity Focused Ultrasound Surgery(MRgFUS) using ExAblate 2000 equipment]
2008     Andalusian Health Technology Assessment Area (AETSA) [Magnetic Resonance imaging for breast cancer diagnostics. Systematic review and economic assessment]
2025     Norwegian Medical Products Agency (NOMA) [Magnetic resonance guided high-intensity focused ultrasound for treatment of essential tremor: single technology assessment]
2012     Andalusian Health Technology Assessment Area (AETSA) [Magnetic resonance guided focused ultrasound for uterine myomas ablation]
2009     Committee for New Health Technology Assessment (CNHTA) [Magnetic remote controlled catheter navigation technique]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Magnetic growth rods for the scoliosis treatment in children]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Macitentan (pulmonary arterial hypertension) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Macitentan - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2019     Haute Autorite de sante (HAS) [Lymphoseek (tilmanocept), radiopharmaceutical for diagnostic use]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium-177 radiolabeled somatostatin analogs in neuroendocrine tumors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium 177 PSMA in patients with prostate cancer]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (non-transfusion-dependent beta-thalassaemia) - Addendum to Commission A23-20]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lusotrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lurasidone - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Lung cryobiopsy in diffuse interstitial lung disease diagnosis]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Lung cancer: investigation, treatment and follow-up algorithms]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lung cancer screening]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lung cancer screening using low-dose computed tomography]
2020     Austrian Institute for Health Technology Assessment (AIHTA) [Lung cancer screening in risk groups]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumasiran (hyperoxaluria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Lumacaftor/Ivacaftor therapy in cystic fibrosis]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, 1 to < 2 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Lower Urinary Tract Symptoms - epidemiology and results from LUTS project Funen on implementation of a clinical guideline in general practice]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Lower respiratory tract infections of a viral origin in the paediatric population: systematic review of Spanish literature]
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [Low-level light therapy for primary dysmenorrhea]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Low-intensity ultrasound for the treatment of fractures]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Low-intensity pulsed ultrasound for the treatment of pseudarthrosis]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Low-dose computed tomography screening for lung cancer]
1999     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Low-back pain: frequency, management and prevention from an HTA perspective]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Low molecular weight heparins versus traditional heparins in thromboembolic diseases]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Low density lipoprotein apheresis as adjuvant treatment for familial hypercholesterolaemia]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Longevity of dental amalgam in comparison to composite materials]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Long-term safety and stability of refractive surgeries in myopia]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Long-acting insulin analogues in the treatment of diabetes mellitus type 2]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Long-acting insulin analogues in the treatment of diabetes mellitus type 1]